TARGETING NEW CANCER SOLUTIONS

No patient should be denied the cancer care they need simply because some options are in short supply or unavailable. Yet, all too often, this is what happens.

LEARN MORE

Source: American Cancer Society

At the core of many oncology therapies are radioisotopes. However, increasingly limited supply inhibits patient outcomes and the development of new therapies.

Innovation

Advancements with radioisotopes

Nusano is combining time-proven technology from universities and world-class research centers with our own breakthrough, patented particle acceleration technology. The result is the first significant advancement in medical radioisotope production in decades – a platform fitting the needs of today and designed for cancer-fighting radiopharmaceuticals of tomorrow.

Inspiration

Life Saving Benefits

Health care has used radioisotopes for decades. But, if supply does not keep up with demand, patients will lose out on the benefits of these lifesaving, proven tools.

Implications

a healthy tomorrow

Nusano’s patented technologies and methods are poised to transform radioisotope production and usher in an exciting new era in cancer care. When it opens, our state-of-the-art facility in West Valley City, Utah will produce radioisotopes quickly, efficiently, and affordably. This will make desperately needed resources available to hospitals and cancer clinics around the world and offer those with life-threatening diseases hope for a healthier tomorrow.

Nusano

Leadership

Nusano is driven by an experienced team of scientists, engineers, and innovators, and guided by leaders with deep expertise in health care, business development and operations.

Chris Lowe

Chief Executive Officer

Chris Lowe is an accomplished business leader with more than 30 years’ experience, the past 20 of which in C-suite and executive-level roles in healthcare and finance. Read more >>

HOWARD C. LEWIN, MD, FACC, FASNC

CO-FOUNDER & CHIEF PRODUCT DEVELOPMENT OFFICER

Dr. Howard Lewin is a globally recognized leader in nuclear cardiology imaging with training in Cardiology and Nuclear Medicine. Read more >>

GLENN B. ROSENTHAL, PH.D.

CO-FOUNDER & CHIEF TECHNOLOGY OFFICER

Dr. Glenn Rosenthal is an accomplished nuclear physicist, and former UCLA research physicist and lecturer.
Read more >>

Pushkar Bedekar

Chief Financial Officer

A 20-year veteran of the pharmaceuticals industry, Bedekar served as the CFO of U.S. Oncology for Novartis prior to joining Nusano. He oversees the company’s financial operations, including accounting, financial planning, tax, and treasury functions.

Kevin Haehl

Chief Product Officer

A 35-year veteran of pharma and biotech, Haehl drives value-creating opportunities for Nusano customers by ensuring excellence throughout the company’s product and supply chain operations.

Chris Ignace

SVP, Scientific Affairs

Ignace spent 13 years at Cardinal Health Nuclear and Precision Solutions in a variety of leadership roles. At Nusano, he applies his deep understanding of radiopharmaceutical development and regulatory processes to drive improved alignment and outcomes for the company and its customers.

Rohan Jain

Chief Commercial Officer

Jain served as VP & Head of Novartis’ U.S. Radioligand Therapy Product Portfolio prior to joining Nusano. His Commercial team works with customers and prospects to enable current and future cancer therapeutics development.

Maggie Kruse

VP, People & Culture

Kruse is a HR executive whose career spans life sciences, financial services, technology, and manufacturing. She is growing Nusano’s innovative, science-driven culture to support current and future radioisotope applications.

Jzaneen Lalani

Chief Business Officer

Lalani has over 20 years’ experience managing life sciences companies across a wide variety of functional areas, including as a general counsel of public and privately-held companies. She oversees Nusano’s HR, legal, government affairs, and special projects functions.

Nusano

Board of Directors

Scott Holbrook

NUSANO BOARD CHAIR & GM-CSO, Pharmalogic

Scott has over twenty years’ experience in the field of molecular imaging and therapeutics.

DELL LOY HANSEN

FOUNDER & CEO, WASATCH GROUP

Dell Loy Hansen is the Founder and Chief Executive Officer of the Wasatch Group and is responsible for the overall management of its enterprises and affiliates.

John dahlstrom

EVP - General Counsel, Wasatch Property Management

John is General Counsel of Wasatch Property Management, a fully integrated real estate development, construction, property management and guaranty capital company operating in six states.

Aaron Gerszewski

Managing Director, Wasatch Equity Partners

Aaron is managing partner at Wasatch Equity Partners, an investment firm with more than $4 billion assets under management.

Andy Harrison

CEO, Section 32

Andy is Managing Director and CEO of Section 32, a venture capital fund investing at the frontiers of technology.

Michael Pellini

Managing Partner, Section 32

Mike is a Managing Partner of Section 32, a venture capital fund investing at the frontiers of technology.

additional directors

company managers

Chris Lowe (CEO) and Howard Lewin (CPDO), also serve on the Board of Directors.

About Nusano

Nusano is a privately held physics company committed to bringing supply stability and innovation to the rapidly emerging and critically undersupplied medical radioisotopes market, and to serving industrial and commercial markets dependent on reliable access to high quality radioisotopes for their products and services. Driven by the company’s proprietary ion source, the Nusano production platform will generate radioisotopes in volumes and varieties exceeding other production methods. Nusano’s breakthrough technologies are poised to help supply the fight against cancer and enable innovation across multiple industries.

Supplying the Fight Against Cancer

Supply chains should not determine a patient’s treatment options. Yet, all too often, this is what happens.

Next-generation cancer therapies are being held back because critical components (medical radioisotopes) needed for advanced therapies and new methods of diagnosis are scarce. Many existing manufacturing techniques for the production of radioisotopes and the facilities relied upon by drugmakers around the world are aging, outdated, inefficient and have limited production capabilities. This threatens the ability to meet current patient needs for medical radioisotopes and stifles innovation.

We need new solutions. That’s where Nusano comes in.

Nusano is a medical radioisotope supplier with a first-of-its-kind radioisotope production platform. Medical radioisotopes are tiny tracers used by doctors to diagnose and treat cancer, Alzheimer’s, heart disease and other diseases. Doctors use medical radioisotopes like flashlights to light up areas inside the body. They can see how blood is flowing, how organs are functioning, even how cells are growing. Advanced medicines and treatment methods also use medical radioisotopes to target and eliminate cancer cells with precision.

Health care has used radioisotopes for decades. But supply hasn’t kept up with demand, leaving patients without the benefits of these lifesaving, proven tools.

Nusano’s patented technologies and methods are poised to transform the production of radioisotopes and help usher in an exciting new era in health care. Opening in 2025, our state-of-the-art radioisotope production platform in West Valley City, Utah will produce radioisotopes quickly, efficiently and affordably. This will make desperately needed medical radioisotopes available to patients around the world and offer those with life-threatening diseases hope for a healthier tomorrow.

Why does Nusano exist?

We believe no patient should be denied the cancer care they need simply because some options are in short supply or unavailable.
Nusano is a radioisotope production company committed to bringing stability and innovation to the rapidly emerging and critically undersupplied medical radioisotopes market.

How does Nusano contribute to the radiopharmaceuticals development?

Nusano is medical radioisotope supplier to drugmakers, hospitals and clinics. With a reliable supply of radioisotopes, these teams can then formulate treatments and next-generation pharmaceuticals needed to advance the fight against cancer.
Nusano has developed a radioisotope production platform that is smaller, safer and more efficient than existing technologies to reliably produce medical radioisotopes at the heart of next-generation cancer treatments and diagnosis techniques.
Radioisotopes are essential components in the active pharmaceutical ingredients (API) of a category of new and emerging cancer therapies, known as radiotherapeutics. Existing supply chains for these treatment-enabling resources are often strained, posing a risk to patient care, clinical trials, and ongoing drug development.

What does Nusano offer?

Nusano is a radioisotope production company making medical radioisotopes that can be targeted to cancer cells with precision –enabling new ways to detect and eradicate cancer and other deadly diseases.
Nusano’s proprietary radioisotope production platform can produce more than 25 isotopes of interest to medicine.
Nusano expects to begin supplying non-carrier-added lutetium-177 (n.c.a. Lu-177) in 2025 and actinium-225 (Ac-225) in 2026.